News

The National Research Council (NRC) of Canada will conduct a final phase of preclinical testing of GB Sciences‘ cannabinoid-based formulations for Parkinson’s disease to determine their mechanisms of action. This final step in testing follows promising results in a fish model of the disease, in which these…

A probiotic strain of the bacteria Bacillus subtilis called PXN21 can prevent the buildup of the protein alpha-synuclein — one of the hallmarks of Parkinson’s disease — in the round worm C. elegans, researchers reports. This finding warrants further investigation to assess the therapeutic potential of dietary…

To heighten awareness of Parkinson’s disease (PD) and inspire patients and their families, Bial Pharmaceuticals has produced a short video to mark World Parkinson’s Day this Saturday, April 11. Called “Keep On Moving,” the production also seeks to destigmatize the neurodegenerative disease and show the diversity and accomplishments…

Therapy given over the phone can help to lessen symptoms of depression in people with Parkinson’s disease, a new study suggests. The study, “Telephone-based cognitive behavioral therapy for depression in Parkinson disease,” was published in Neurology. Although often thought of as a movement disorder, Parkinson’s non-motor…

Aspen Neuroscience has raised $70 million to advance the development of  Parkinson’s disease therapies using patients’ own cells. The products, ANPD001 and ANPD002, are the first-ever Parkinson’s treatments designed to use a patient’s own cells as a replacement to restore neuronal function and to modify disease progression.

On four occasions during Parkinson’s Awareness Month, which is observed every April, some 500 members of the global Parkinson’s (PD) community will participate in the first virtual Parkinson’s Sing-A-Long. Presented by the World Parkinson Coalition (WPC), the effort will be led by the WPC’s choir director,…

People with Parkinson’s disease can face “hidden sorrows” during the COVID-19 pandemic, like increased stress and limits on physical activity, that could worsen their symptoms. But ways exist to mitigate these “less visible” threats of social distancing and other changes in daily routines. Indeed, the pandemic may facilitate wider…

The Phase 2 RESTORE-1 trial testing the investigational gene therapy VY-AADC has suspended the screening and enrollment of new Parkinson’s disease patients to evaluate the impact of the COVID-19 pandemic on the study’s protocols and on the safety of participants, Voyager Therapeutics has announced. Patient enrollment…

Roche presented initial data from an ongoing Phase 2 clinical trial evaluating prasinezumab (PRX002/RG7935) — an antibody against the alpha-synuclein protein — in more than 300 people with early stage Parkinson’s disease. Data highlighted that the trial’s participants, including those on MAO-B inhibitors, represent a wider population…

As the world frantically battles coronavirus, a leading Dutch neurologist warns of the next global pandemic — and this one, he says, is almost entirely of our own making. Bastiaan Bloem, MD, a neurologist and professor at Radboud University Nijmegen Medical Center, says that over the next 20 years,…